Hereditary Angioedema: A Review of the Current and Evolving Treatment Landscape

被引:7
|
作者
Betschel, Stephen D. [1 ]
Banerji, Aleena [2 ,9 ]
Busse, Paula J. [3 ]
Cohn, Danny M. [4 ]
Magerl, Markus [5 ,6 ,7 ,8 ]
机构
[1] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON, Canada
[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[3] Icahn Sch Med Mt Sinai, Div Allergy & Clin Immunol, New York, NY 10029 USA
[4] Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Amsterdam, Netherlands
[5] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[6] Free Univ Berlin, Berlin, Germany
[7] Humboldt Univ, Berlin, Germany
[8] Fraunhofer Inst Translat Med & Pharmacol ITMP, Dept Immunol & Allergol, Berlin, Germany
[9] Harvard Med Sch, Massachusetts Hosp, Yawkey 4,55 Fruit St, Boston, MA 02114 USA
关键词
Hereditary angioedema; C1 ESTERASE INHIBITOR; ACUTE ATTACKS; C1-INHIBITOR CONCENTRATE; INTERNATIONAL CONSENSUS; PEDIATRIC-PATIENTS; DOUBLE-BLIND; ECALLANTIDE; MANAGEMENT; PATIENT; SAFETY;
D O I
10.1016/j.jaip.2023.04.017
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is a rare disease characterized by sudden and often unprovoked episodes of swelling that can be potentially life-threatening when it involves the upper airway. The treatment options for both acute episodes of HAE and LTP, used to minimize the frequency and severity of angioedema attacks, were limited historically to very few options, had considerable side effects, and/or had consider-able burden of treatment. Fortunately, through the elucida-tion of the pathophysiology of HAE, the development of newer targeted therapies has been possible both for acute therapy and long-term prophylaxis and even more are on the horizon. Because of the rapid development of these therapies, it can be challenging for clinicians to keep abreast of newer and developing treatments for HAE. This review article will outline the current and potential future treatments for HAE. It will also highlight important considerations when treating special HAE patient populations including women and pe-diatric patients. & COPY; 2023 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2023;11:2315-25)
引用
收藏
页码:2315 / 2325
页数:11
相关论文
共 50 条
  • [21] Lanadelumab: A Review in Hereditary Angioedema
    Yahiya Y. Syed
    Drugs, 2019, 79 : 1777 - 1784
  • [22] The Genetics of Hereditary Angioedema: A Review
    Santacroce, Rosa
    D'Andrea, Giovanna
    Maffione, Angela Bruna
    Margaglione, Maurizio
    d'Apolito, Maria
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (09)
  • [23] Hereditary angioedema: a current state-of-the-art review, I: introduction
    Bernstein, Jonathan A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (01) : S1 - S1
  • [24] Clinical manifestations of hereditary angioedema and a systematic review of treatment options
    Rosi-Schumacher, Mattie
    Shah, Sejal J.
    Craig, Timothy
    Goyal, Neerav
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2021, 6 (03): : 394 - 403
  • [25] Current Management Options for Hereditary Angioedema
    Bork, Konrad
    CURRENT ALLERGY AND ASTHMA REPORTS, 2012, 12 (04) : 273 - 280
  • [26] Current and Emerging Therapeutics in Hereditary Angioedema
    Do, Toan
    Riedl, Marc A.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2024, 44 (03) : 561 - 576
  • [27] Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema
    Frank, Michael M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (01) : S23 - S29
  • [28] Hereditary angioedema - current and future therapies
    Aygoeren-Puersuen, E.
    ALLERGOLOGIE, 2019, 42 (01) : 31 - 38
  • [29] Current Management Options for Hereditary Angioedema
    Konrad Bork
    Current Allergy and Asthma Reports, 2012, 12 : 273 - 280
  • [30] Current drugs in early development for hereditary angioedema: potential for effective treatment
    Bork, Konrad
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) : 887 - 891